Redmile Group LLC lessened its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 10.6% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 13,257,286 shares of the biopharmaceutical company’s stock after selling 1,571,035 shares during the quarter. Amicus Therapeutics makes up approximately 5.7% of Redmile Group LLC’s investment portfolio, making the stock its 2nd biggest holding. Redmile Group LLC’s holdings in Amicus Therapeutics were worth $156,171,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently bought and sold shares of FOLD. Vanguard Group Inc. lifted its holdings in shares of Amicus Therapeutics by 5.0% in the 4th quarter. Vanguard Group Inc. now owns 28,492,486 shares of the biopharmaceutical company’s stock worth $404,308,000 after acquiring an additional 1,360,613 shares during the last quarter. Norges Bank bought a new stake in Amicus Therapeutics in the fourth quarter worth about $35,915,000. UBS Group AG lifted its stake in Amicus Therapeutics by 58.1% in the fourth quarter. UBS Group AG now owns 824,708 shares of the biopharmaceutical company’s stock worth $11,703,000 after purchasing an additional 303,038 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Amicus Therapeutics by 32.6% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 2,415,090 shares of the biopharmaceutical company’s stock valued at $34,270,000 after buying an additional 593,131 shares during the period. Finally, Teachers Retirement System of The State of Kentucky bought a new position in shares of Amicus Therapeutics during the fourth quarter valued at approximately $1,178,000.
Amicus Therapeutics Stock Down 0.7 %
NASDAQ:FOLD traded down $0.07 during mid-day trading on Monday, reaching $10.11. The company’s stock had a trading volume of 3,829,157 shares, compared to its average volume of 2,816,233. The company has a quick ratio of 2.61, a current ratio of 3.03 and a debt-to-equity ratio of 2.97. Amicus Therapeutics, Inc. has a 1 year low of $9.02 and a 1 year high of $14.57. The stock has a fifty day moving average of $10.09 and a 200-day moving average of $11.21. The firm has a market capitalization of $2.99 billion, a PE ratio of -20.63 and a beta of 0.71.
Analyst Ratings Changes
FOLD has been the subject of a number of research analyst reports. UBS Group decreased their price target on Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, May 10th. Bank of America decreased their target price on Amicus Therapeutics from $14.00 to $13.00 and set a “buy” rating for the company in a research report on Friday, May 10th. Wells Fargo & Company assumed coverage on shares of Amicus Therapeutics in a report on Thursday, May 30th. They issued an “overweight” rating and a $18.00 price target on the stock. Morgan Stanley reduced their price target on shares of Amicus Therapeutics from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Friday, May 10th. Finally, Guggenheim raised shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Tuesday, May 14th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $17.57.
Read Our Latest Stock Analysis on Amicus Therapeutics
Insiders Place Their Bets
In other news, CEO Bradley L. Campbell sold 6,100 shares of Amicus Therapeutics stock in a transaction on Friday, July 5th. The stock was sold at an average price of $10.00, for a total value of $61,000.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,866,540. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $10.07, for a total transaction of $75,525.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $8,928,605.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bradley L. Campbell sold 6,100 shares of Amicus Therapeutics stock in a transaction on Friday, July 5th. The stock was sold at an average price of $10.00, for a total transaction of $61,000.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at $8,866,540. The disclosure for this sale can be found here. 2.20% of the stock is owned by company insiders.
Amicus Therapeutics Profile
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Read More
- Five stocks we like better than Amicus Therapeutics
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Survey: Top 175 Fittest Retirement Locations in America
- About the Markup Calculator
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- How to Use the MarketBeat Stock Screener
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report).
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.